肺動脈性肺高血圧症市場- 世界の産業規模、シェア、動向、機会、予測、2018年～2028年薬剤クラス別、タイプ別、投与経路別、地域別、競合で区分

世界の肺動脈性肺高血圧症（PAH）市場は、2022年に66億6,000万米ドルの評価額に達し、予測期間を通じて大幅な成長が見込まれ、年間平均成長率（CAGR）は5.32%で、2028年には90億6,000万米ドルに達すると予測されています。

肺動脈性肺高血圧症は、心臓から肺に血液を運ぶ肺動脈の血圧上昇を特徴とする、まれではあるが深刻な病状です。この状態は肺動脈の狭窄と硬化を引き起こし、心臓への負担を増大させ、心不全を引き起こす可能性があります。

世界の肺動脈性肺高血圧症（PAH）市場には、PAHを管理し対処するために設計された様々な医薬品、医療機器、治療戦略が含まれています。医学的理解、革新的な治療法、PAHに対する意識の高まりなど、最近の市場開拓がこの市場の成長促進要因となっています。この成長の要因には、座りがちなライフスタイルや肥満などの危険因子によるPAHの有病率の増加、診断能力の向上、患者とヘルスケア専門家の両方における意識の高まりなどがあります。

薬物療法はPAHの管理において極めて重要な役割を担っており、PAHの発症に関連する特定の経路を標的とする薬剤が用いられています。プロスタサイクリン類似物質、エンドセリン受容体拮抗薬、ホスホジエステラーゼ5型阻害薬などのこれらの薬剤は、血管を拡張し、動脈圧を下げ、疲労や息切れなどの症状を緩和することを目的としています。

さらに、肺血管拡張ポンプのような医療機器や補助人工心臓のような埋め込み型機器は、PAHの重症例管理に貢献しています。従来の治療と並行して、患者のQOLを高めるために生活習慣の改善や定期的な運動が推奨されています。しかし、治療費の高さや専門医療へのアクセスの制限など、PAH市場には課題が残っています。さらに、PAH診断の複雑さや専門的な知識の必要性が、タイムリーな介入の妨げになることもあります。

主な市場促進要因

• 1.PAHの有病率の上昇と認知度の向上：PAHの有病率の上昇とその重症度に対する認知度の向上が、PAH市場の拡大を後押ししています。公衆衛生キャンペーン、医学教育の改善、患者支援活動が早期診断と早期介入に貢献しています。
• 2.革新的な治療アプローチ：PAHの根本的なメカニズムをターゲットとした医薬品の進歩は、治療状況を一変させました。革新的な薬剤や医療機器により、患者の転帰や生活の質が改善されています。
• 3.個別化医療：個々の患者のプロファイルに合わせた医療の動向は重要な傾向です。遺伝子検査、分子プロファイリング、標的療法は、治療効果と患者関与を最適化します。

主な市場課題

• 1.高い治療費：PAH治療薬、医療機器、専門的ケアにかかる費用は、患者やヘルスケアシステムにとって経済的課題となります。効果的な治療や包括的ケアへのアクセスが損なわれる可能性があります。
• 2.認知度の低さ：患者や医療従事者の認識不足は、診断の遅れ、最適な治療、限られた研究費につながります。教育やアドボカシー活動を通じて認知度を高めることが重要です。
• 3.主要医薬品の特許切れ：特許の期限切れは、治療へのアクセス、手頃な価格、技術革新に影響を与えます。患者が手頃な価格で治療を受けられるようにすることと、医薬品の技術革新のバランスをとることが不可欠。

主な市場動向

• 1.共同調査と世界ネットワーク：国際的なパートナーシップとネットワークは、知識の交換、学際的なアプローチ、革新的な治療法や治療ガイドラインの開発の加速を促進します。
• 2.個別化治療アプローチ：遺伝学と分子プロファイルに基づく個別化医療は、PAH治療に変革をもたらしつつあります。正確な診断と標的治療により、治療効果と患者のエンパワーメントが向上します。

セグメント別の洞察

• 1.薬剤クラス別洞察：シルデナフィルやタダラフィルなどのホスホジエステラーゼ5阻害薬は、肺血管を弛緩させ症状を緩和する作用があるため、PAH市場を独占しています。
• 2.タイプの洞察：有効性と安全性が確立されたブランド薬は、ジェネリック医薬品が利用可能であるにもかかわらず、PAH治療の主要な選択肢であり続けています。

地域別洞察

北米がPAH市場をリードしているのは、高度なヘルスケアインフラ、強力な研究イニシアティブ、規制当局の支援によるものです。同地域では、医療機関間の連携、啓発キャンペーン、患者支援活動が、疾患管理と転帰の改善に寄与しています。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 肺動脈性肺高血圧症の世界市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 薬剤クラス別（プロスタサイクリンおよびプロスタサイクリンアナログ、カルシウム拮抗薬、ホスホジエステラーゼ5、エンドセリン受容体拮抗薬、その他）
  • タイプ別（ブランド、ジェネリック）
  • 投与経路別（経口、静脈内/皮下、吸入）
  • 企業別（2022年）
  • 地域別
• 市場マップ

第6章 北米肺動脈性肺高血圧症市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 薬剤クラス別
  • タイプ別
  • 投与経路別
  • 国別
• 北米国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州肺動脈性肺高血圧症市場の展望

• 市場規模および予測
  • 金額別
• 市場シェアと予測
  • 薬剤クラス別
  • タイプ別
  • 投与経路別
  • 国別
• 欧州国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋肺動脈性肺高血圧症市場の展望

• 市場規模および予測
  • 金額別
• 市場シェアと予測
  • 薬剤クラス別
  • タイプ別
  • 投与経路別
  • 国別
• アジア太平洋地域国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米肺動脈性肺高血圧症市場の展望

• 市場規模および予測
  • 金額別
• 市場シェアと予測
  • 薬剤クラス別
  • タイプ別
  • 投与経路別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカ肺動脈性肺高血圧症市場の展望

• 市場規模および予測
  • 金額別
• 市場シェアと予測
  • 薬剤クラス別
  • タイプ別
  • 投与経路別
  • 国別
• MEA：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 PESTLE分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Business Overview
• Company Snapshot
• Product & Services
• Financials（In case of listed companies）
• Recent Developments
• SWOT Analysis
  • Gilead Sciences, Inc.
  • Viatris Inc.
  • Sandoz Inc.（Novartis）
  • Johnson & Johnson
  • Sun Pharmaceutical Industries, Inc.
  • Lupin Pharmaceuticals, Inc.
  • GlaxoSmithKline LLC
  • Johnson & Johnson
  • Bayer AG
  • United Therapeutics Corporation

第16章 戦略的提言

The Global Pulmonary Arterial Hypertension (PAH) Market reached a valuation of USD 6.66 Billion in 2022 and is expected to experience substantial growth throughout the forecast period, projecting a Compound Annual Growth Rate (CAGR) of 5.32% and expected to reach USD 9.06 Billion through 2028. Pulmonary Arterial Hypertension is a rare but serious medical condition characterized by elevated blood pressure in the pulmonary arteries, which carry blood from the heart to the lungs. This condition leads to the narrowing and stiffening of these arteries, placing increased strain on the heart and potentially resulting in heart failure.

The Global Pulmonary Arterial Hypertension (PAH) Market encompasses various pharmaceuticals, medical devices, and treatment strategies designed to manage and address PAH. Recent developments in medical understanding, innovative therapies, and heightened awareness of PAH have been key drivers of growth in this market. Factors contributing to this growth include the increasing prevalence of PAH due to risk factors like sedentary lifestyles and obesity, as well as improved diagnostic capabilities and heightened awareness among both patients and healthcare professionals.

Pharmaceutical interventions play a pivotal role in managing PAH, with drugs targeting specific pathways associated with the disease's pathogenesis. These medications, such as prostacyclin analogs, endothelin receptor antagonists, and phosphodiesterase type 5 inhibitors, aim to dilate blood vessels, reduce arterial pressure, and alleviate symptoms like fatigue and shortness of breath.

Moreover, medical devices like pulmonary vasodilator pumps and implantable devices like ventricular assist devices contribute to managing severe cases of PAH. Alongside conventional therapies, lifestyle modifications and regular exercise are recommended to enhance patients' quality of life. However, challenges persist within the PAH market, including the high cost of treatment and limited access to specialized care. Additionally, the complexity of PAH diagnosis and the need for specialized expertise can hinder timely intervention.

The outlook of the market is characterized by ongoing research and development efforts focused on discovering novel therapies and improving treatment outcomes. Emerging trends such as personalized medicine approaches, biomarker identification, and combination therapies show promise in tailoring treatments to individual patient needs.

In conclusion, the Global Pulmonary Arterial Hypertension (PAH) Market is undergoing significant transformation due to innovative therapies and medical advancements. As awareness of the condition increases and research continues, the market is poised to witness further developments in diagnostics, treatment options, and patient care, ultimately leading to improved outcomes for those affected by this challenging medical condition.

Key Market Drivers

• 1. Increasing Prevalence and Awareness of PAH: The rising prevalence of PAH and growing awareness of its severity have driven the expansion of the PAH Market. Public health campaigns, improved medical education, and patient advocacy initiatives have contributed to early diagnosis and intervention.

• 2. Innovative Therapeutic Approaches: Pharmaceutical advancements targeting PAH's underlying mechanisms have transformed the treatment landscape. Innovative drugs and medical devices are improving patient outcomes and quality of life.

• 3. Personalized Medicine: Tailoring medical care to individual patient profiles is a significant trend. Genetic testing, molecular profiling, and targeted therapies optimize treatment efficacy and patient engagement.

Key Market Challenges

• 1. High Treatment Costs: The cost of PAH medications, medical devices, and specialized care poses financial challenges for patients and healthcare systems. Access to effective treatments and comprehensive care can be compromised.

• 2. Limited Awareness: Lack of awareness among patients and healthcare professionals leads to delayed diagnosis, suboptimal care, and limited research funding. Raising awareness through education and advocacy is crucial.

• 3. Patent Expiration of Key Drugs: Patent expiration affects treatment accessibility, affordability, and innovation. Balancing patients' access to affordable treatments with pharmaceutical innovation is essential.

Key Market Trends

• 1. Collaborative Research and Global Networks: International partnerships and networks facilitate knowledge exchange, interdisciplinary approaches, and accelerated development of innovative therapies and treatment guidelines.

• 2. Personalized Treatment Approaches: Personalized medicine, driven by genetics and molecular profiles, is transforming PAH care. Precise diagnostics and targeted therapies enhance treatment efficacy and patient empowerment.

Segmental Insights

• 1. Drug Class Insights: Phosphodiesterase 5 inhibitors, such as sildenafil and tadalafil, dominate the PAH Market due to their ability to relax pulmonary blood vessels and alleviate symptoms.

• 2. Type Insights: Branded medications, with established efficacy and safety records, continue to be the primary choice in PAH treatment, despite the availability of generics.

Regional Insights

North America leads the PAH Market due to advanced healthcare infrastructure, robust research initiatives, and regulatory support. Collaborations among medical institutions, awareness campaigns, and patient advocacy efforts contribute to improved disease management and outcomes in the region.

Key Market Players

• Gilead Sciences, Inc.
• Viatris Inc.
• Sandoz Inc. (Novartis)
• Johnson & Johnson
• Sun Pharmaceutical Industries, Inc.
• Lupin Pharmaceuticals, Inc.
• GlaxoSmithKline LLC
• Johnson & Johnson
• Bayer AG
• United Therapeutics Corporation

Report Scope:

In this report, the Global Pulmonary Arterial Hypertension Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Pulmonary Arterial Hypertension Market, By Drug Class:

• Prostacyclin and Prostacyclin Analogs
• Calcium Channel Blockers
• Phosphodiesterase 5
• Endothelin Receptor Antagonist
• Others

Pulmonary Arterial Hypertension Market, By Type:

• Branded
• Generics

Pulmonary Arterial Hypertension Market, By Route Of Administration:

• Oral
• Intravenous/ Subcutaneous
• Inhalational

Global Pulmonary Arterial Hypertension Market, By region:

• North America
• United States
• Canada
• Mexico
• Asia-Pacific
• China
• India
• South Korea
• Australia
• Japan
• Europe
• Germany
• France
• United Kingdom
• Spain
• Italy
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Pulmonary Arterial Hypertension Market.

Available Customizations:

• Global Pulmonary Arterial Hypertension Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customers

5. Global Pulmonary Arterial Hypertension Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Prostacyclin and Prostacyclin Analogs, Calcium Channel Blockers, Phosphodiesterase 5, Endothelin Receptor Antagonist and Others)
  • 5.2.2. By Type (Branded, Generics)
  • 5.2.3. By Route Of Administration (Oral, Intravenous/ Subcutaneous, Inhalational)
  • 5.2.4. By Company (2022)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Pulmonary Arterial Hypertension Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Type
  • 6.2.3. By Route Of Administration
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pulmonary Arterial Hypertension Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Route Of Administration
  • 6.3.2. Mexico Pulmonary Arterial Hypertension Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Route Of Administration
  • 6.3.3. Canada Pulmonary Arterial Hypertension Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Route Of Administration

7. Europe Pulmonary Arterial Hypertension Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Type
  • 7.2.3. By Route Of Administration
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Pulmonary Arterial Hypertension Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Route Of Administration
  • 7.3.2. Germany Pulmonary Arterial Hypertension Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Route Of Administration
  • 7.3.3. United Kingdom Pulmonary Arterial Hypertension Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Route Of Administration
  • 7.3.4. Italy Pulmonary Arterial Hypertension Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By Route Of Administration
  • 7.3.5. Spain Pulmonary Arterial Hypertension Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By Route Of Administration

8. Asia-Pacific Pulmonary Arterial Hypertension Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Type
  • 8.2.3. By Route Of Administration
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Pulmonary Arterial Hypertension Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Route Of Administration
  • 8.3.2. India Pulmonary Arterial Hypertension Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Route Of Administration
  • 8.3.3. South Korea Pulmonary Arterial Hypertension Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Route Of Administration
  • 8.3.4. Japan Pulmonary Arterial Hypertension Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By Route Of Administration
  • 8.3.5. Australia Pulmonary Arterial Hypertension Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By Route Of Administration

9. South America Pulmonary Arterial Hypertension Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Type
  • 9.2.3. By Route Of Administration
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Pulmonary Arterial Hypertension Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Route Of Administration
  • 9.3.2. Argentina Pulmonary Arterial Hypertension Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Route Of Administration
  • 9.3.3. Colombia Pulmonary Arterial Hypertension Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Route Of Administration

10. Middle East and Africa Pulmonary Arterial Hypertension Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Type
  • 10.2.3. By Route Of Administration
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Pulmonary Arterial Hypertension Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By Route Of Administration
  • 10.3.2. Saudi Arabia Pulmonary Arterial Hypertension Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By Route Of Administration
  • 10.3.3. UAE Pulmonary Arterial Hypertension Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By Route Of Administration

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Business Overview
• 15.2. Company Snapshot
• 15.3. Product & Services
• 15.4. Financials (In case of listed companies)
• 15.5. Recent Developments
• 15.6. SWOT Analysis
  • 15.6.1. Gilead Sciences, Inc.
  • 15.6.2. Viatris Inc.
  • 15.6.3. Sandoz Inc. (Novartis)
  • 15.6.4. Johnson & Johnson
  • 15.6.5. Sun Pharmaceutical Industries, Inc.
  • 15.6.6. Lupin Pharmaceuticals, Inc.
  • 15.6.7. GlaxoSmithKline LLC
  • 15.6.8. Johnson & Johnson
  • 15.6.9. Bayer AG
  • 15.6.10. United Therapeutics Corporation

16. Strategic Recommendations